title: A meta-analysis of efficacy and safety of doripenem for treating bacterial infections.
abstract: OBJECTIVE
  The aim of this article is to compare the efficacy and safety of doripenem for bacterial infections.
  
  
  METHODS
  We included six randomized clinical trials identified from PubMed and Embase up to July 31, 2014. The included trials compared efficacy and safety of doripenem for complicated intra-abdominal infections, complicated urinary tract infection, nosocomial pneumonia, and acute biliary tract infection. The meta-analysis was carried on by the statistical software of Review Manager, version 5.2.
  
  
  RESULTS
  Compared with empirical antimicrobial agents on overall treatment efficacy, doripenem was associated with similar clinical and microbiological treatment success rates (for the clinical evaluable population, odds ratio [OR]=1.26, 95% confidence interval [CI] 0.93-1.69, p=0.13; for clinical modified intent-to-treatment population, OR=0.88, 95% CI 0.55-1.41, p=0.60; for microbiology evaluable population, OR=1.16, 95% CI 0.90-1.50, p=0.26; for microbiological modified intent-to-treatment (m-mITT), OR=0.98, 95% CI 0.81-1.20, p=0.87). We compared incidence of adverse events and all-cause mortality to analyze treatment safety. The outcomes suggested that doripenem was similar to comparators in terms of incidence of adverse events and all-cause mortality on modified intent-to-treatment population (for incidence of AEs, OR=1.10, 95% CI 0.90-1.35, p=0.33; for all-cause mortality, OR=1.08, 95% CI 0.77-1.51, p=0.67). In nosocomial pneumonia and ventilator-associated pneumonia treatment, doripenem was not inferior to other antibacterial agents in terms of efficacy and safety.
  
  
  CONCLUSIONS
  From this meta-analysis, we can conclude that doripenem is as valuable and well-tolerated than empirical antimicrobial agents for complicated intra-abdominal infections, complicated urinary tract infection, acute biliary tract infection and nosocomial pneumonia treatment.
authors: Department of Pharmacy, The First Hospital of Jilin University, Changchun 130021, PR China. Electronic address: 350740439@qq.com.
authors: Xiao-Yu
authors: XY
authors: Qu
authors: Department of Technical Center, Jilin Entry Exit Inspection and Quarantine Bureau, Changchun 130062, PR China.
authors: Ting-Ting
authors: TT
authors: Hu
authors: Department of Pharmacy, The First Hospital of Jilin University, Changchun 130021, PR China.
authors: Wei
authors: W
authors: Zhou
mesh_terms: D000208:Acute Disease; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy*; D015780:Carbapenems / Q000009:adverse effects / Q000627:therapeutic use*; D002761:Cholangitis / Q000188:drug therapy; D003428:Cross Infection / Q000188:drug therapy*; D000077726:Doripenem; D006801:Humans; D018410:Pneumonia, Bacterial / Q000188:drug therapy; D053717:Pneumonia, Ventilator-Associated / Q000188:drug therapy; D016032:Randomized Controlled Trials as Topic; D014552:Urinary Tract Infections / Q000188:drug therapy
chemical_list: D000900:Anti-Bacterial Agents; D015780:Carbapenems; D000077726:Doripenem
keywords: Doripenem; Efficacy; Infection; Meta-analysis; Safety
references: Crit Care Med. 2008 Apr;36(4):1089-96
references: 18379232
references: Infect Drug Resist. 2009;2:41-9
references: 21694886
references: Curr Med Res Opin. 2008 Jul;24(7):2113-26
references: 18549664
references: Clin Ther. 2008 May;30(5):868-83
references: 18555934
references: Crit Care. 2012 Nov 13;16(6):R218
references: 23148736
references: Int J Antimicrob Agents. 2013 Apr;41(4):388-92
references: 23410792
references: Diagn Microbiol Infect Dis. 2009 Apr;63(4):415-25
references: 19249175
references: BMJ. 2003 Sep 6;327(7414):557-60
references: 12958120
references: Curr Med Res Opin. 2009 Dec;25(12):3029-36
references: 19849650
references: Antimicrob Agents Chemother. 2010 May;54(5):2119-24
references: 20211892
references: Control Clin Trials. 1996 Feb;17(1):1-12
references: 8721797
references: Antimicrob Agents Chemother. 2009 Sep;53(9):3782-92
references: 19581455
references: Toxicology. 2006 May 1;222(1-2):114-24
references: 16549226
references: Ther Clin Risk Manag. 2007 Oct;3(5):789-94
references: 18473003
references: J Gastroenterol. 2015 Feb;50(2):221-9
references: 24795092